A PhI CXCR3 Antagonist Making Progress in its Clinical Development for Inflammatory Disorders

Please copy the URL and add it into your RSS Feed Reader.

Facebook X Linkedin Weibo

Download PDF

Synfacts 2023; 19(06): 0619
DOI: 10.1055/s-0042-1752686

Innovative Drug Discovery and Development

Contributor(s):

Antonia F. Stepan (Roche)

,

Erika A. Crane (Drug Hunter, Inc.)

CXCR3 - CYP2D6 - inflammation - clinical candidate

Article published online:
11 May 2023

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany